Nuvectis Pharma, Inc. $NVCT Shares Sold by Baldwin Wealth Partners LLC MA

Baldwin Wealth Partners LLC MA lowered its position in Nuvectis Pharma, Inc. (NASDAQ:NVCT) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 350,461 shares of the company’s stock after selling 8,000 shares during the period. Baldwin Wealth Partners LLC MA’s holdings in Nuvectis Pharma were worth $2,618,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in NVCT. Iridian Asset Management LLC CT acquired a new stake in shares of Nuvectis Pharma during the 1st quarter valued at approximately $2,481,000. Goldman Sachs Group Inc. acquired a new stake in shares of Nuvectis Pharma during the 1st quarter valued at approximately $446,000. Jane Street Group LLC acquired a new stake in shares of Nuvectis Pharma during the 1st quarter valued at approximately $413,000. Austin Wealth Management LLC acquired a new stake in shares of Nuvectis Pharma during the 1st quarter valued at approximately $393,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Nuvectis Pharma during the 1st quarter valued at approximately $321,000. Institutional investors and hedge funds own 96.77% of the company’s stock.

Nuvectis Pharma Price Performance

Shares of Nuvectis Pharma stock opened at $6.01 on Friday. Nuvectis Pharma, Inc. has a 1 year low of $4.44 and a 1 year high of $11.80. The company has a market capitalization of $153.01 million, a P/E ratio of -5.14 and a beta of -0.29. The business has a 50 day moving average price of $6.35 and a 200 day moving average price of $7.93.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.05). As a group, research analysts expect that Nuvectis Pharma, Inc. will post -1.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on NVCT shares. Wall Street Zen downgraded shares of Nuvectis Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, June 29th. Weiss Ratings restated a “sell (e+)” rating on shares of Nuvectis Pharma in a research report on Wednesday. Finally, HC Wainwright cut their price objective on Nuvectis Pharma from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, August 4th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $15.33.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.